ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 34,006,567 shares, a decrease of 3.7% from the February 15th total of 35,317,685 shares. Approximately 29.4% of the company’s shares are sold short. Based on an average daily trading volume, of 1,310,304 shares, the short-interest ratio is currently 26.0 days.
Hedge funds have recently added to or reduced their stakes in the business. Chevy Chase Trust Holdings Inc. bought a new position in ZIOPHARM Oncology during the 3rd quarter worth about $104,000. G&S Capital LLC bought a new position in ZIOPHARM Oncology during the 4th quarter worth about $125,000. Metropolitan Life Insurance Co. NY bought a new position in ZIOPHARM Oncology during the 4th quarter worth about $139,000. Adell Harriman & Carpenter Inc. bought a new position in ZIOPHARM Oncology during the 3rd quarter worth about $141,000. Finally, Steward Partners Investment Advisory LLC bought a new position in ZIOPHARM Oncology during the 3rd quarter worth about $145,000. Hedge funds and other institutional investors own 40.19% of the company’s stock.
ZIOPHARM Oncology (ZIOP) opened at $4.39 on Tuesday. The stock has a market capitalization of $623.22, a PE ratio of -8.13 and a beta of 1.42. ZIOPHARM Oncology has a 1-year low of $3.33 and a 1-year high of $7.88.
A number of analysts recently commented on ZIOP shares. Raymond James Financial restated a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Thursday, December 14th. ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. BidaskClub upgraded ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Finally, Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a report on Saturday, January 6th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.50.
COPYRIGHT VIOLATION WARNING: “ZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 3.7% in February” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/03/13/ziopharm-oncology-inc-ziop-short-interest-down-3-7-in-february.html.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.